利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.01 秒)

    S-omeprazole magnesium
    1.
    发明授权
    S-omeprazole magnesium 失效
    S-奥美拉唑镁

    公开(公告)号：US07553857B2

    公开(公告)日：2009-06-30

    申请号：US11318236

    申请日：2005-12-23

    申请人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    发明人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    IPC分类号： A61K31/4439 ,  C07D401/12

    CPC分类号： C07D401/12

    摘要： The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a-sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1 % by weight as determined by high performance liquid chromatography (HPLC).

    摘要翻译： 本发明公开了一种制备S-奥美拉唑镁盐的方法。 S-奥美拉唑盐的水含量优选低于约4.8重量％，镁含量为约3.4-4.0重量％，以无水，无溶剂的S-奥美拉唑镁的重量计，其光学纯度为 至少约85％的对映异构体过量（“ee”）。 此外，本发明提供了基本上不含中性奥美拉唑的S-奥美拉唑镁盐，意味着该产品含有小于约3重量％的中和S-奥美拉唑和中性奥美拉唑的总和。 此外，根据本发明的S-奥美拉唑镁优选具有通过高效液相色谱（HPLC）测定的相关物质和降解产物的测定值小于约0.1重量％。

    S-omeprazole magnesium
    2.
    发明授权
    S-omeprazole magnesium 有权
    S-奥美拉唑镁

    公开(公告)号：US07875723B2

    公开(公告)日：2011-01-25

    申请号：US12416537

    申请日：2009-04-01

    申请人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    发明人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    IPC分类号： C07D401/12

    CPC分类号： C07D401/12

    摘要： The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1% by weight as determined by high performance liquid chromatography (HPLC).

    摘要翻译： 本发明公开了一种制备S-奥美拉唑镁盐的方法。 S-奥美拉唑盐的水含量优选低于约4.8重量％，镁含量为约3.4-4.0重量％，以无水，无溶剂的S-奥美拉唑镁的重量计，其光学纯度为 至少约85％的对映异构体过量（“ee”）。 此外，本发明提供了基本上不含中性奥美拉唑的S-奥美拉唑的镁盐，意味着该产品含有小于约3重量％的中性S-奥美拉唑和中性奥美拉唑的总和。 此外，根据本发明的S-奥美拉唑镁优选具有通过高效液相色谱（HPLC）测定的相关物质和降解产物的测定值小于约0.1重量％。

    CRYSTALLINE SOLVATE OF OMEPRAZOLE SODIUM
    3.
    发明申请
    CRYSTALLINE SOLVATE OF OMEPRAZOLE SODIUM 有权
    OMEPRAZOLE SODIUM的结晶溶剂

    公开(公告)号：US20090221646A1

    公开(公告)日：2009-09-03

    申请号：US11916462

    申请日：2006-06-07

    申请人： Lidija Vranicar Savanovic ,  Zoran Ham ,  Janez Rzen

    发明人： Lidija Vranicar Savanovic ,  Zoran Ham ,  Janez Rzen

    IPC分类号： A61K31/4439 ,  C07D401/12

    CPC分类号： C07D401/12

    摘要： The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation, which acts as intermediary compound to the processes for its conversion into different crystalline forms, first of all to a known omeprazole sodium form A, with low amount of residual solvents, i.e. less than 0.5% by weight of residual solvent.The present invention also relates to novel crystalline omeprazole sodium form E and crystalline omeprazole sodium form F as well to the processes for their preparation as well, both with considerably low levels of residual solvents.Omeprazole sodium form A and both novel crystalline forms omeprazole sodium form E and form F are useful for the treatment of gastrointestinal disorders.

    摘要翻译： 本发明属于制药工业领域，涉及新型结晶奥美拉唑钠乙醇溶剂合物及其制备方法，其作为其转化为不同结晶形式的方法的中间体化合物，首先是已知的奥美拉唑 钠形式A，残留溶剂量少，即残留溶剂的重量少于0.5％。 本发明还涉及新的结晶奥美拉唑钠形式E和结晶奥美拉唑钠形式F以及其制备方法以及相当低水平的残留溶剂。 奥美拉唑钠形式A和两种新型结晶形式奥美拉唑钠形式E和形式F可用于治疗胃肠道疾病。

    Crystalline solvate of omeprazole sodium
    4.
    发明授权
    Crystalline solvate of omeprazole sodium 有权
    奥美拉唑钠的结晶溶剂化物

    公开(公告)号：US08247566B2

    公开(公告)日：2012-08-21

    申请号：US11916462

    申请日：2006-06-07

    申请人： Lidija Vranicar Savanovic ,  Zoran Ham ,  Janez Rzen

    发明人： Lidija Vranicar Savanovic ,  Zoran Ham ,  Janez Rzen

    IPC分类号： C07D401/12

    CPC分类号： C07D401/12

    摘要： The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation, which acts as intermediary compound to the processes for its conversion into different crystalline forms, first of all to a known omeprazole sodium form A, with low amount of residual solvents, i.e. less than 0.5% by weight of residual solvent.The present invention also relates to novel crystalline omeprazole sodium form E and crystalline omeprazole sodium form F as well to the processes for their preparation as well, both with considerably low levels of residual solvents.Omeprazole sodium form A and both novel crystalline forms omeprazole sodium form E and form F are useful for the treatment of gastrointestinal disorders.

    摘要翻译： 本发明属于制药工业领域，涉及新型结晶奥美拉唑钠乙醇溶剂合物及其制备方法，其作为其转化为不同结晶形式的方法的中间体化合物，首先是已知的奥美拉唑 钠形式A，残留溶剂量少，即残留溶剂的重量少于0.5％。 本发明还涉及新的结晶奥美拉唑钠形式E和结晶奥美拉唑钠形式F以及其制备方法以及相当低水平的残留溶剂。 奥美拉唑钠形式A和两种新型结晶形式奥美拉唑钠形式E和形式F可用于治疗胃肠道疾病。

    S-Omeprazole Magnesium
    8.
    发明申请
    S-Omeprazole Magnesium 有权
    S-奥美拉唑镁

    公开(公告)号：US20100087652A1

    公开(公告)日：2010-04-08

    申请号：US12416537

    申请日：2009-04-01

    申请人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    发明人： Lidija Vranicar Savanovic ,  Dejan Mandic ,  Renata Toplak Casar

    IPC分类号： C07D401/12

    CPC分类号： C07D401/12

    摘要： The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1% by weight as determined by high performance liquid chromatography (HPLC).

    摘要翻译： 本发明公开了一种制备S-奥美拉唑镁盐的方法。 S-奥美拉唑盐的水含量优选低于约4.8重量％，镁含量为约3.4-4.0重量％，以无水，无溶剂的S-奥美拉唑镁的重量计，其光学纯度为 至少约85％的对映异构体过量（“ee”）。 此外，本发明提供了基本上不含中性奥美拉唑的S-奥美拉唑的镁盐，意味着该产品含有小于约3重量％的中性S-奥美拉唑和中性奥美拉唑的总和。 此外，根据本发明的S-奥美拉唑镁优选具有通过高效液相色谱（HPLC）测定的相关物质和降解产物的测定值小于约0.1重量％。